Sentence examples for identification of surrogate from inspiring English sources

Furthermore, the identification of surrogate biomarkers that could predict the long term effectiveness of treatment (on survival) early on during a clinical trial could alleviate the costs but shortening the length of clinical investigations unlikely to be successful.

This article outlines how to build whole-cell models, which have applications in the understanding of disease processes, the identification of surrogate markers, drug metabolism, safety assessment and bioprocess design.

Identification of the causal component(s) may result in the identification of surrogate assays that can assist in the formulation of TIVs to minimise the future incidence of febrile reactions in the paediatric population.

It is also extremely important to optimize techniques for the testing and production of new vaccines including the quantitation of immune responses in animals and in humans, identification of surrogate markers of immune protection, streamlined vaccine production, and rapid evaluation of candidate vaccines for testing in clinical trials.

To overcome the difficulty in obtaining tumour samples, several groups have focused on the identification of surrogate markers.

These findings are interesting as GGT fraction analysis may contribute to further identification of surrogate markers of NAFLD that may be linked to cardiovascular disease.

Identification of surrogates in clinical practice facilitates diagnosis of organ damage at a stage when fatal consequences can be avoided by adequate treatment.

Very long cores and CplusT's gave lower performance in terms of % correct because very long (e.g. 100 cM) haplotypes are more varied and have a lower frequency, making both the identification of surrogates and the HLI more difficult.

Identification of surrogates of a proband as individuals who show no opposing homozygotes with that proband across long strings of consecutive loci is easily disrupted by both genotype and mapping errors.

The identification of appropriate surrogate endpoints for evaluating cancer therapeutics has been of ongoing interest across various tumor types.

An important focus in planning a proof-of- concept program can be the identification of a surrogate end point, which is predictive of the primary phase III end point.